SUNPHARMA · NSE
Sun Pharmaceutical Industries Limited
₹1,837.3
-1.61% (-₹30)
Prev. close
₹1,867.3
Volume
28,96,860
Delivery %
72.3%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Sun Pharma for the next six months, recommending a buy between ₹1,930 and ₹1,970 with a target of ₹2,250 and …” | Pabitro MukherjeeBajaj Broking | Sun Pharmaceutical Industries Ltd | PENDING |
Fundamentals
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Dilip Shantilal Shanghvi
Headquarters
Mumbai
Employees
47,000
Website
sunpharma.comExchange
View on NSE ↗Key stats
Market cap
₹4.48 L Cr
P/E ratio (TTM)
37.0
Dividend yield
0.86%
EPS (TTM)
₹50.42
Beta (1Y · daily vs NIFTY 50)
0.48
Beta (5Y · monthly vs NIFTY 50)
0.84
Shares float
106.49 Cr
EPS · quarter ended Jun 2026
₹12.10
Upcoming earnings
05 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹33,498.14 Cr | ₹38,654.49 Cr | ₹43,885.68 Cr | ₹48,496.85 Cr | ₹52,578.44 Cr | ₹58,462.04 Cr | |
| EBITDA | ₹5,020.75 Cr | ₹6,752.41 Cr | ₹12,109.86 Cr | ₹13,883.00 Cr | ₹16,558.88 Cr | ₹18,395.64 Cr |
| ₹2,903.82 Cr | ₹3,272.73 Cr | ₹8,473.58 Cr | ₹9,576.38 Cr | ₹10,929.04 Cr | ₹11,479.42 Cr | |
| Diluted EPS | ₹12.1 | ₹13.6 | ₹35.3 | ₹39.9 | ₹45.6 | ₹47.8 |
Net income for at least one year shown could not be independently verified against the company's own annual report — the two sources disagree for at least one overlapping year, so the year(s) this deck cannot verify are left blank rather than shown with an unverified number.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹67,666.73 Cr | ₹69,807.77 Cr | ₹80,743.59 Cr | ₹85,462.88 Cr | ₹92,100.58 Cr | ₹1.09 L Cr | |
| ₹3,868.58 Cr | ₹1,290.30 Cr | ₹6,885.87 Cr | ₹3,273.67 Cr | ₹2,362.19 Cr | ₹4,627.32 Cr | |
| Stockholders' equity | ₹46,462.78 Cr | ₹48,011.22 Cr | ₹55,995.38 Cr | ₹63,666.75 Cr | ₹72,218.02 Cr | ₹83,570.09 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,170.37 Cr | ₹8,984.54 Cr | ₹4,959.33 Cr | ₹12,134.98 Cr | ₹14,072.09 Cr | ₹12,419.18 Cr | |
| Investing cash flow | ₹536.22 Cr | ₹-5,724.74 Cr | ₹-7,943.68 Cr | ₹-690.20 Cr | ₹-5,306.16 Cr | ₹-11,344.05 Cr |
| ₹-5,980.48 Cr | ₹-5,193.46 Cr | ₹2,376.07 Cr | ₹-6,710.16 Cr | ₹-7,905.82 Cr | ₹-2,512.55 Cr | |
| Capital expenditure | ₹-1,170.13 Cr | ₹-1,495.04 Cr | ₹-2,085.58 Cr | ₹-2,201.81 Cr | ₹-2,128.58 Cr | ₹-3,609.37 Cr |
| End cash position | ₹6,273.03 Cr | ₹4,508.25 Cr | ₹4,623.73 Cr | ₹9,285.65 Cr | ₹10,268.77 Cr | ₹9,770.51 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 54.48% |
| Public | 45.52% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Show all 13
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
60 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Taro Pharmaceutical Industries stock gains on Sun Pharma merger cash offer
Taro Pharmaceutical Industries stock is gaining as a cash merger with Sun Pharmaceutical Industries is finalized. Shareholders will receive $32.25 per share as of September 17, 2026, converting equity into a fixed cash payout. This move aligns with Sun Pharma's strategy to consolidate subsidiaries and streamline its corporate structure.
Sun Pharmaceutical Industries falls Tuesday, outperforms competitors
MarketWatch · 3 days ago